​

Cidara Therapeutics (CDTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CDTX Stock Forecast

Cidara Therapeutics (CDTX) stock forecast, based on 2 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $12.00 and a low of $12.00. This represents a -32.77% decline from the last price of $17.85.

- $6 $12 $18 $24 $30 High: $12 Avg: $12 Low: $12 Last Closed Price: $17.85

CDTX Stock Rating

Cidara Therapeutics stock's rating consensus is Buy, based on 2 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 2 0 2 Strong Sell Sell Hold Buy Strong Buy

CDTX Forecast vs Benchmarks

TypeNameUpside
StockCidara Therapeutics-32.77%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$12.00
Last Closing Price$17.85$17.85$17.85
Upside/Downside---32.77%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2532---5
Dec, 2432---5
Nov, 24531--9
Oct, 24531--9
Sep, 24531--9
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 14, 2024Ed ArceH.C. Wainwright$12.00$6.4386.63%-32.77%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Aug 14, 2024H.C. WainwrightBuyupgrade
May 12, 2022NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-35 $-28 $-21 $-14 $-7 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.74$-0.84$-0.43$-0.26-----
Avg Forecast$-30.90$-17.67$-8.33$-5.60$-24.17$-9.59$-9.50$-8.39$-4.60
High Forecast$-31.31$-17.90$-8.71$-5.60$-24.17$-9.59$-17.63$-17.31$-4.60
Low Forecast$-30.49$-17.43$-7.88$-5.60$-24.17$-9.59$-3.41$-3.06$-4.60
Surprise %-94.37%-95.25%-94.84%-95.36%-----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.07M$49.57M$64.29M$63.91M-----
Avg Forecast$18.53M$46.64M$64.69M$60.25M$5.03M$53.59M$132.54M$10.83M$62.41M
High Forecast$18.35M$46.17M$61.97M$60.25M$5.03M$53.59M$132.54M$10.83M$62.41M
Low Forecast$18.72M$47.11M$66.96M$60.25M$5.03M$53.59M$132.54M$10.83M$62.41M
Surprise %-34.89%6.28%-0.62%6.07%-----

Net Income Forecast

$-110M $-90M $-70M $-50M $-30M $-10M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-72.37M$-43.91M$-29.80M$-22.93M-----
Avg Forecast$-49.20M$-77.23M$-35.59M$-22.93M$-105.63M$-41.91M$-45.98M$-44.51M$-20.11M
High Forecast$-59.04M$-78.24M$-52.32M$-32.57M$-105.63M$-41.91M$-77.07M$-75.65M$-20.11M
Low Forecast$-39.36M$-76.21M$-18.86M$-13.30M$-105.63M$-41.91M$-14.89M$-13.37M$-20.11M
Surprise %47.10%-43.14%-16.27%------

CDTX Forecast FAQ

Is Cidara Therapeutics stock a buy?

Cidara Therapeutics stock has a consensus rating of Buy, based on 2 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cidara Therapeutics is a favorable investment for most analysts.

What is Cidara Therapeutics's price target?

Cidara Therapeutics's price target, set by 2 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $12 at the low end to $12 at the high end, suggesting a potential -32.77% change from the previous close price of $17.85.

How does Cidara Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Cidara Therapeutics stock forecast shows a -32.77% downside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Cidara Therapeutics over the past three months?

  • January 2025: 60.00% Strong Buy, 40.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 60.00% Strong Buy, 40.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 55.56% Strong Buy, 33.33% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Cidara Therapeutics’s EPS forecast?

Cidara Therapeutics's average annual EPS forecast for its fiscal year ending in December is -24.17 for 2024, a 9196.15% increase from the reported $-0.26 in 2023. The prediction for 2025 is $-9.59, $-9.5 for 2026, $-8.39 for 2027, and $-4.6 for 2028.

What is Cidara Therapeutics’s revenue forecast?

Cidara Therapeutics's average annual revenue forecast for its fiscal year ending in December is $5.03M for 2024, a -92.12% decrease from the reported $63.9M in 2023. The forecast for 2025 is $53.59M, $132.54M for 2026, $10.83M for 2027, and $62.41M for 2028.

What is Cidara Therapeutics’s net income forecast?

For its fiscal year ending in December, Cidara Therapeutics's average annual net income forecast is $-106M for 2024, reflecting an 360.66% increase from the reported $-22.931M in 2023. The projection for 2025 is $-41.907M, $-45.978M for 2026, $-44.51M for 2027, and $-20.108M for 2028.